What type of treatment is pemetinib/pemetinib?

Pemigatinib is a targeted therapy drug that belongs to the class of tyrosine kinase inhibitors. It effectively treats certain types of cancer by specifically targeting the fibroblast growth factor receptor (FGFR) to interfere with the growth and proliferation of cancer cells. Members of the FGFR family, including FGFR1, FGFR2, FGFR3, and FGFR4, are involved in physiological processes such as cell growth, division, repair, and angiogenesis under normal circumstances. However, in some cancers, especially cholangiocarcinomaand other malignant tumors,rearrangements or mutations of the FGFR gene may lead to excessive activation of the receptor, thereby promoting the proliferation and metastasis of tumor cells.

Pemetinib is specifically used to target patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 gene rearrangement, especially those who are ineffective or resistant to traditional chemotherapy. This makes pemetinib a member of precision therapy. Its therapeutic mechanism is to inhibit the kinase activity of FGFR and prevent tumor cells from being dependent on growth factors, thereby inhibiting tumor growth and expansion. Through this mechanism, pemetinib can significantly improve the therapeutic effect of patients with FGFR gene abnormalities, has relatively minor side effects, and is more selective than traditional chemotherapy drugs.

Different from traditional chemotherapy drugs, pemetinib is a targeted drug that mainly targets the specific molecular mechanisms of cancer cells for treatment. The advantage of targeted drugs is that they can accurately identify and inhibit specific disease-causing genes or receptors in cancer cells, reducing the impact on normal healthy cells, thereby mitigating common side effects during treatment. The targeted therapeutic properties of pemetinib make it an important drug for the treatment of patients with cholangiocarcinoma and other tumors with FGFR gene abnormalities.

Reference materials:https://go.drugbank.com/drugs/DB15102